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Mechanism of urate crystal-
induced inflammation
Gouty nephropathy and gouty arthritis are thought to be 
produced by deposition of monosodium urate crystals in 
cells or in the extracellular space. Th is results in attraction 
of infl ammatory cells. Recent studies by Martinon et al. 
have considerably advanced our understanding of this 
process. It had been known for some time that interleukin-
1β (IL-1β) is involved. Th e authors found that incubation of 
monocytes with urate crystals results in activation of IL-1β, 
whose precursor protein needs to be clipped by caspase-1 
to produce the active infl ammatory and pyrogenic factor. 
Th ey demonstrated that urate crystals engage what is now 
known as the ‘infl ammasome’ — a group of proteins including 
NALP1, -2, or -3 hooked together by the adaptor protein 
ASC, which, in turn, connects the complex to caspase-1. Th is 
engagement resulted in the production of active IL-1β and IL-
18. Macrophages from mice defi cient in various components 
of the infl ammasome, such as caspase-1, ASC, and NALP3, 
were defective in crystal-induced IL-1β activation. Moreover, 
an impaired neutrophil infl ux was found in an in vivo model 
of crystal-induced peritonitis in infl ammasome-defi cient 
mice and mice defi cient in the IL-1β receptor. Remarkably, 
the same studies repeated using another crystal — calcium 
pyrophosphate dehydrate, the causative agent of pseudogout 
— resulted in the same reactions. Th ese studies provide 
a remarkable advance in the fi eld of ‘autoinfl ammatory’ 
diseases such as periodic fevers and Behçet’s syndrome in 
which activation of IL-1β has been implicated. It is likely that 
these insights apply to gouty nephropathy as well as to gouty 
arthritis, but such an association has to be tested. (Nature 
2006; 440: 237–241)
Qais Al-Awqati
Alternative pathway of 
angiotensin II generation in 
diabetes
Angiotensin (Ang) II is a key mediator of diabetic vascular 
and renal complications. Although angiotensin-converting 
enzyme (ACE) is the main Ang II-generating enzyme, there 
is accumulating evidence suggesting alternative pathways. 
Chymase, a serine protease fi rst identifi ed in mast cells but 
also expressed in vascular smooth muscle, mesangial, and 
some epithelial cells, is capable of cleaving Ang I to Ang II. 
Indeed, overexpression of chymase in transgenic mice causes 
hypertension, and chymase inhibitors have benefi cial eff ects 
in animal models of vascular injury. Furthermore, a number 
of clinical trials in diabetic nephropathy demonstrated that 
dual blockade of Ang II using Ang receptor blockers and ACE 
inhibitors was more eff ective in slowing disease progression 
as compared with ACE inhibitors alone. It was also found that 
vascular chymase was upregulated in diabetic nephropathy,1 
but the mechanism responsible for this eff ect is unknown. 
In a recent study,2 Koka et al. examined whether advanced 
glycation end products (AGEs) induced vascular chymase 
expression and thus chymase-dependent Ang II generation. 
Th ey found that chymase was upregulated in coronary 
and renal arteries in diabetic patients, and this change was 
associated with deposition of AGEs, increased expression of 
the receptor for AGEs (RAGE), and activation of extracellular 
signal-regulated kinase (ERK)1/2 MAP kinase. In vitro, 
AGEs induced chymase expression and chymase-dependent 
Ang II generation in human vascular smooth muscle cells 
via the RAGE–ERK1/2 MAP kinase-dependent mechanism. 
AGE-induced vascular chymase expression was inhibited by 
a neutralizing RAGE antibody, by inhibiting ERK1/2 MAP 
kinase activities, and by overexpression of the dominant-
negative ERK1/2. When compared with ACE, chymase 
contributed to the majority of Ang II production in response 
to AGEs. Hence, the study showed that AGEs, a hallmark of 
diabetes-related renal and vascular complications, induced 
chymase via the RAGE–ERK1/2 MAP kinase pathway. In 
turn, chymase initiated an alternative Ang II-generating 
pathway, a potential contributor in the pathogenesis of 
diabetic vascular and renal disease. (1J Am Soc Nephrol 2003; 
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Treating prehypertension lowers 
risk of hypertension
Prehypertension, a precursor of stage 1 hypertension, is a 
predictor of cardiovascular risk.  In a new study published in 
the New England Journal of Medicine, Julius et al. investigated 
whether pharmacologic treatment with an angiotensin 
receptor blocker, candesartan, prevented or postponed stage 1 
hypertension in patients with prehypertension. A total of 809 
participants with systolic pressure of 130–139 mm Hg and 
diastolic pressure of 89 mm Hg or lower, or systolic pressure of 
139 mm Hg or lower and diastolic pressure of 85–89 mm Hg, 
were randomized to candesartan or placebo for 2 years, followed 
by 2 years of placebo for both groups. During the fi rst 2 years, 
hypertension developed in 154 participants in the placebo group 
and 53 in the candesartan group (relative risk reduction, 66.3%). 
Aft er 4 years, hypertension had developed in 240 participants in 
the placebo group and 208 in the candesartan group (relative risk 
reduction, 15.6%). Serious adverse events occurred in 3.5% of 
those receiving candesartan and 5.9% of those receiving placebo. 
Over the 4-year study period, stage 1 hypertension developed in 
nearly two-thirds of the placebo group. Th e researchers conclude 
that treatment of prehypertension with candesartan was eff ective 
in lowering the incidence of hypertension and appeared to be 
well tolerated. (N Engl J Med advance online publication, March 
14, 2006, doi:10.1056/NEJMoa060838)
Jai Radhakrishnan
Hormonal treatment reduces 
retroperitoneal fibrosis
Retroperitoneal fi brosis (RF), a rare condition marked by scar 
tissue behind the abdomen, is normally treated by surgical 
removal of the tissue. But complete surgical removal is oft en 
impossible, so drug treatments are of interest. Tamoxifen, a drug 
that blocks the eff ects of estrogen, has been shown to treat RF in 
individual patients. Van Bommel et al. conducted a trial to assess 
the safety and effi  cacy of tamoxifen in treating RF. A total of 19 
patients with RF who were seen over a 6-year period at a Dutch 
medical center were prescribed tamoxifen. Doctors measured 
changes in symptoms, signs of infl ammation, and the size of scar 
tissue every few months. Tamoxifen treated RF successfully in 14 
of the 19 patients. Symptoms improved within weeks, and signs 
of infl ammation decreased and the scar tissue shrank within 
months. RF returned in one patient aft er the drug was withdrawn 
but improved when therapy was started again. Of the fi ve patients 
who did not improve while taking tamoxifen, three did well on a 
combination of drugs that suppress the immune system. None of 
the patients experienced any serious side eff ects. Th e researchers 
did not compare tamoxifen with surgery or other drugs. Th e 
authors note the limitations of their fi ndings: they do not show 
that tamoxifen is better than other treatments and do not 
demonstrate safety or effi  cacy for longer than 2 years. Th erefore, 
the authors conclude that tamoxifen can be considered an option 
for the treatment of patients with RF. But its safety and effi  cacy 
over a long period of time and compared with other treatments 
are not known. (Ann Intern Med 2006; 144: 101–106)
Detlef Schlöndorﬀ 
Transforming growth factor-β 
signaling as a mechanism of 
hypertension
Transforming growth factor-β (TGF-β) plays a critical role 
in many renal diseases. In an article published in the journal 
Cell, Zacchigna et al. showed that TGF-β may be a pathogenic 
factor in arterial hypertension. Increased systemic vascular 
resistance in hypertension is attributed to changes in vascular 
smooth muscle or endothelial function. However, recent work 
has attracted attention to the extracellular matrix of the vascular 
wall as a regulator of vascular resistance and, hence, arterial 
pressure. Th e authors provided additional support for this view 
by analyzing mice lacking Emilin1, a secreted glycoprotein 
associated with the extracellular matrix of blood vessels. Emilin1 
knockout mice were viable but showed narrower arteries and 
elevated arterial pressure with increased systemic vascular 
resistance. Cardiac function and vascular reactivity were 
normal, so that the increased resistance was probably due to the 
structural vascular abnormalities. Th e mechanism by which 
Emilin1 controlled vessel diameter appeared to be TGF-β, as it 
interacted with the immature form of TGF-β, proTGF-β, and 
prevented its maturation by furin convertases. Indeed, Emilin1-
defi cient mice showed unopposed TGF-β signaling, and the 
smaller size of their blood vessels was attributed to the cytostatic 
role of TGF-β. Remarkably, reduction of TGF-β gene dosage in 
Emilin1-defi cient mice resulted in the normalization of blood 
pressure with increased arterial diameter and decreased vascular 
resistance. Th ese exciting results open a new avenue of research 
in arterial hypertension and highlight the importance of the 
arterial wall architecture in determining arterial pressure. (Cell 
2006; 124: 929–942) 
Reprinted from Cell vol. 124, “Emilin1 links TGF-β maturation to blood 
pressure homeostasis,” by Zacchigna et al., pp. 929–942, copyright 2006, 
with permission from Elsevier.
